In Depth 9 Oct 2024
Promising cure for COPD: Is a breakthrough treatment within reach?
Find out whether a promising cure for COPD is within reach, after recent advancements in treatments and research around the disease.
- Latest Posts
In Depth 8 Oct 2024
Top biotech deals of September 2024
There were a number of deals that stirred the biopharma industry in September. We have listed the major collaborations that took place last month.
How an innovative, data-driven approach is revolutionizing drug discovery for solid tumors
Learn how cancer tissue biobanks and insights into solid tumor heterogeneity are transforming drug discovery and paving the way for innovative treatments.
In Depth 7 Oct 2024
Spinal cord injury: Are we getting closer to a treatment?
Delve into the spinal cord injury treatment landscape with a few pharmaceutical approaches that could tackle this complex condition.
In Depth 4 Oct 2024
The biggest private biotech investments in September 2024
The companies Candid Therapeutics, ArsenalBio, and eGenesis bagged the biggest private biotech investments in September 2024.
Podcast 4 Oct 2024
Targeting telomerase to disrupt cancer
Listen to our conversation with Vlad Vitoc, CEO of MAIA, on the pioneering approach of telomere targeting
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 3 Oct 2024
Six biotechs driving progress in Duchenne muscular dystrophy
In this article, we take a look at six clinical-stage biotechs that are fostering R&D in the Duchenne muscular dystrophy therapeutic space.
News and Trends 3 Oct 2024
Resolution Therapeutics raises $85 million to advance its macrophage therapy
Find out about Resolution Therapeutics’ macrophage therapy, as it just raised $85 million in a series B round.
News and Trends 2 Oct 2024
Niemann-Pick disease: FDA approves first two drugs in the space of a week for rare disorder
Find out all about the first two FDA drug approvals for the rare genetic disorder Niemann-Pick disease type C.
Best in Biotech 1 Oct 2024
Lithuania’s biotech: Six companies to put on your radar
Here are six companies at the forefront of Lithuania’s growing biotech scene, showcasing innovations in protein engineering and gene editing.
Sublingual delivery: the future for GLP-1 receptor agonists
Discover how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual delivery method.
News and Trends 30 Sep 2024
The race for a bird flu vaccine: milestones and breakthroughs
The recent uptick in U.S. bird flu cases poses a threat to public health. Biotechs are now developing vaccines to mitigate the outbreak.
ADVERTISEMENT
